Planning Ahead: Maintenance Therapy in Endometrial Cancer
The Food and Drug Administration (FDA) recently approved immune checkpoint inhibitors (ICIs) for patients with advanced or recurrent endometrial cancer (EC) who did not respond to first-line treatment with chemotherapy. This led to several new trials of emerging therapies, including …